Literature DB >> 20191624

Second salvage surgery for re-recurrent oral cavity and oropharynx carcinoma.

Ivan Marcelo Gonçalves Agra1, João Gonçalves Filho, Everton Pontes Martins, Luiz Paulo Kowalski.   

Abstract

BACKGROUND: Salvage surgery is considered the best treatment approach for patients with recurrent oral carcinoma. Unfortunately, 50% to 60% of the patients who undergo salvage surgery will develop further locoregional recurrence, and they are not usually considered for further treatment. Our aim in this study was to report our experience with a second salvage surgery for selected patients with re-recurrent oral cavity and oropharyngeal squamous cell carcinoma (SCC).
METHODS: Forty-one patients underwent a second salvage surgical procedure, with curative intention for re-recurrent oral cancer. The surgical treatment used was wide local resection in 34 cases, neck dissection in 9 cases, and isolated neck dissection in 7 cases.
RESULTS: Cancer-specific survival (CSS) rate in 3 years was at 20%. Patients with re-recurrence in <6 months presented 3-year CSS null, whereas patients with re-recurrence after 6 months presented 3-year CSS of 32.3% (p = .007).
CONCLUSION: Second salvage surgery can be considered a potentially curative therapeutic approach for a selected group of patients with re-recurrent oral SCC. The disease-free interval was the main clinical factor associated with the prognosis. 2010 Wiley Periodicals, Inc. Head Neck, 2010.

Entities:  

Mesh:

Year:  2010        PMID: 20191624     DOI: 10.1002/hed.21298

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  When is reoperative surgery not indicated for recurrent head and neck squamous cell carcinoma?

Authors:  Juan P Rodrigo; Luiz P Kowalski; Carl E Silver; Remco de Bree; Alessandra Rinaldo; Ashok R Shaha; Primož Strojan; Mohamed N Elsheikh; Missak Haigentz; Alvaro Sanabria; H Hakan Coskun; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-26       Impact factor: 2.503

2.  Overexpression of HSBP1 is associated with resistance to radiotherapy in oral squamous epithelial carcinoma.

Authors:  Lanhua Shen; Rui Zhang; Yi Sun; Xin Wang; An-Mei Deng; Liangjia Bi
Journal:  Med Oncol       Date:  2014-05-11       Impact factor: 3.064

3.  Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy.

Authors:  Molly E Heft Neal; Julia Brennan; Catherine T Haring; J Chad Brenner; Francis Worden; Paul Swiecicki; Michelle Mierzwa; Keith A Casper; Kelly M Malloy; Chaz L Stucken; Scott A McLean; Mark E Prince; Carol R Bradford; Gregory T Wolf; Andrew G Shuman; Steven B Chinn; Douglas B Chepeha; Andrew J Rosko; Matthew E Spector
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-19       Impact factor: 2.503

4.  Prognostic value of pretreatment ¹⁸F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma.

Authors:  Nai-Ming Cheng; Joseph Tung-Chieh Chang; Chung-Guei Huang; Din-Li Tsan; Shu-Hang Ng; Hung-Ming Wang; Chun-Ta Liao; Chien-Yu Lin; Cheng-Lung Hsu; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-02       Impact factor: 9.236

Review 5.  Salvage Surgery in Recurrent Oral Squamous Cell Carcinoma.

Authors:  K S Rathan Shetty; Vinayak Kurle; P Greeshma; Veena B Ganga; Samskruthi P Murthy; Siddappa K Thammaiah; P Krishna Prasad; Purushottham Chavan; Rajshekar Halkud; R Krishnappa
Journal:  Front Oral Health       Date:  2022-01-28

6.  Recurrent oral cancer: current and emerging therapeutic approaches.

Authors:  Sabrina Daniela da Silva; Michael Hier; Alex Mlynarek; Luiz Paulo Kowalski; Moulay A Alaoui-Jamali
Journal:  Front Pharmacol       Date:  2012-07-30       Impact factor: 5.810

7.  In vivo Biocompatibility, Biodistribution and Therapeutic Efficiency of Titania Coated Upconversion Nanoparticles for Photodynamic Therapy of Solid Oral Cancers.

Authors:  Sasidharan Swarnalatha Lucky; Niagara Muhammad Idris; Kai Huang; Jaejung Kim; Zhengquan Li; Patricia Soo Ping Thong; Rong Xu; Khee Chee Soo; Yong Zhang
Journal:  Theranostics       Date:  2016-07-18       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.